Innate Pharma SA
Laure-Hélène Mercier, EVP, Finance and Corporate Strategy, joined Innate Pharma in 2007 and was appointed Chief Financial Officer in December 2016. Prior to her current position, Ms. Mercier served as Executive Vice President, Finance beginning in October 2016 and was previously our Director of Investor Relations. Prior to joining, Ms. Mercier held positions as an equity analyst at Oddo Securities and Natexis Bleichroeder. She has a MSc in Neurosciences from Université Aix-Marseille and a MBA from ESSEC Business School.
This person is not in any offices
Innate Pharma SA
2 followers
Innate Pharma SA is a France-based biopharmaceutical Company that develops drugs for treatment of cancer and inflammatory diseases. The Company identifies and characterizes drug candidates, selects indications and manages the pre-clinical and clinical development of products. Innate Pharma primarily focuses on the development of new therapeutic solutions and monoclonal antibodies for the treatment of cancer, as well as for the treatment of infectious diseases and chronic inflammatory pathologies. The Company develops two categories of immunotherapies: immuno-modulators and cytotoxic antibodies. The Company works in collaboration with Bristol-Myers Squibb for Phase I cancer antibody program and with Novo Nordisk A/S for two antibody programs in inflammation treatment. The Company operates through anti-NKG2A antibody, an immune checkpoint inhibitor ready for Phase II development in oncology from Novo Nordisk.